(EN) A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
CAPItello-292
NCT04862663
 Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
 HOPITAL FLEURIMONT
|
|
Michelle Roy
819-346-1110 poste 12848
|
(EN) A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
MAC30/BR009
NCT05879926
Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Michelle Roy
819-346-1110 poste 12848
|
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
ELISA
NCT04797299
Actif en recrutement
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
|
Marie-Ève Caron
819-697-3333 poste 63238
|
(EN) A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
MK-2870-012
NCT06393374
Actif en recrutement
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
|
|
(EN) Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy
ROSALIE
NCT05866458
Actif en recrutement
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
|
Marie-Ève Caron
819-697-3333 poste 63238
|
(EN) A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
TROPION-Breast04
NCT06112379
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Gladys El Helou
514-340-8222 poste 26581
|
(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
WO44263
NCT05894239
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Wagdy Rezk
514-340-8222 poste 28248
|
(EN) Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
EXActDNA-003 /? NSABP B-64
NCT06401421
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Herve Rendos
514-340-8222
|
(EN) A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
BO45853
NCT07054190
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
|
(EN) Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer
Saci-IO TNBC
NCT04468061
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Aline Mamo
514-340-8222 poste 5525
|
Groupe d'étude en oncologie du Québec